利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.013 秒)

    Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
    1.
    发明申请
    Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM 有权
    Mnk激活能源家畜和有机物代谢调控中涉及的同种异体蛋白

    公开(公告)号：US20120045452A1

    公开(公告)日：2012-02-23

    申请号：US13245188

    申请日：2011-09-26

    申请人： Arnd Steuernagel ,  Karsten Eulenberg ,  Günter Brönner ,  Thomas Ciossek ,  Bettina Rudolph ,  Dorothea Rudolph ,  Funmi Belgore ,  Stefan Jäkel ,  Christoph Meyer

    发明人： Arnd Steuernagel ,  Karsten Eulenberg ,  Günter Brönner ,  Thomas Ciossek ,  Bettina Rudolph ,  Dorothea Rudolph ,  Funmi Belgore ,  Stefan Jäkel ,  Christoph Meyer

    IPC分类号： A61K31/7088 ,  A61P1/18 ,  G01N33/573 ,  C12Q1/48 ,  C12Q1/68 ,  A61K39/395 ,  A61P3/10

    CPC分类号： C12N9/1205 ,  A61K38/45 ,  Y10S514/909

    摘要： This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.

    摘要翻译： 本发明涉及MAP激酶相互作用激酶（Mnk）基因家族的核酸序列及其编码的氨基酸序列的用途，以及使用Mnk核酸或多肽，特别是Mnk激酶抑制剂和激活剂的这些序列或效应物， 在与体重调节和产热相关的疾病和病症的诊断和治疗中。 本公开的一个方面包括识别具有升高的胰腺功能障碍或发展中的可能性的动物或人的方法，所述方法包括：（a）从动物或人类受试者获得生物样品; 和（b）从生物样品中确定受试者是否具有Mnk2和/或Mnk1基因的遗传变体或其同源物，或所述Mnk2和/或Mnk1基因的表达产物或其同源物，其中所述遗传变异体为 与胰腺功能障碍的发生概率相关。

    Pyrrolopyrimidines for pharmaceutical compositions
    4.
    发明授权
    Pyrrolopyrimidines for pharmaceutical compositions 有权
    用于药物组合物的吡咯并嘧啶

    公开(公告)号：US08697713B2

    公开(公告)日：2014-04-15

    申请号：US12373224

    申请日：2007-07-10

    申请人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    发明人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    IPC分类号： A01N43/90 ,  A61K31/519 ,  C07D487/00

    CPC分类号： C07D487/04

    摘要： The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

    摘要翻译： 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。

    PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    5.
    发明申请
    PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS 有权
    药物组合物的吡咯并吡啶

    公开(公告)号：US20100105708A1

    公开(公告)日：2010-04-29

    申请号：US12373224

    申请日：2007-07-10

    申请人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    发明人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    IPC分类号： A61K31/519 ,  C07D487/04 ,  A61P3/00 ,  A61P29/00

    CPC分类号： C07D487/04

    摘要： The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

    摘要翻译： 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。